Pharma & Biotech Global Week in Review 5 Oct 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Angiomax (Bivalirudin) – Teva drops attempts to void Angiomax patents, but will supply Medicines Company with the active ingredient (The IP Factor) (GenericsWeb)

US: Rep. McCaul seeks to reinvigorate interest in the Creating Hope Act of 2011; introduces companion bill in the House (FDA Law Blog)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Nagoya Protocol on biodiversity benefit-sharing has 64 signatories (IP Watch)

Book review Monday: Development and Health in Poor Countries (Patent Baristas)

EU: OHIM Boards of Appeal: pharmaceutical products and cosmetics: Case R 877/2010-2 (Class 46)

India: Conducting a post-mortem on Astella’s Indian patent no: 234753 (Spicy IP)

India: Delhi High Court passes ex-parte interim injunction against Symed Labs for alleged infringement of Indian Patent No: 221536: Vifor v Symed (Spicy IP)

India: Patent laws on genes and gene sequences (IIPRD Blog)

US: Prometheus v Mayo SCOTUS argument set for December 7, 2011 (Maier & Maier)

US: Generic Pharmaceutical Association releases report on value of pay-for-delay agreements (Patent Docs)

US: FDA Biosimilar Guidelines complete, awaiting publication (Patent Docs)

US: A flurry of generic drug labeling carve-out citizen petitions; scorecard updated (FDA Law Blog)

US: Rep. McCaul seeks to reinvigorate interest in the Creating Hope Act of 2011; introduces companion bill in the House (FDA Law Blog)

US: FDA issues draft guidance proposing to streamline the de novo classification process (FDA Law Blog)

US: Precision BioSciences asserts its patent covering ‘Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity’ against Cellectis (Patent Docs)

 

Products

Aloxi (Palonosetron hydrochloride) – US: Helsinn Healthcare files patent infringement suit against Teva following Para IV certification (Patent Docs)

Angiomax (Bivalirudin) – Teva drops attempts to void Angiomax patents, but will supply Medicines Company with the active ingredient (The IP Factor) (GenericsWeb)

Glivec (Imatinib) – India: Glivec patent dispute: the case so far (Part I) (Patent Circle)

Lovenox (Enoxaparin) – US: Momenta files for preliminary injunction against Amphastar, Watson Pharmaceuticals and International Medical Systems (GenericsWeb)

Nexavar (Sorafenib) – India: Taking a closer look at the Nexavar litigation (Spicy IP)

Valsartan – Denmark: Supreme Court decision concerning conditions for injunction (Kluwer Patent Blog)

Valsartan – France: Valsartan in France: a clarification — and an apology (The SPC Blog)

Viagra (Sildenafil) – Russia: Pfizer starts Viagra case against Teva in Russia (GenericsWeb)

Zemplar (Paricalcitol) – US/Portugal: Hospira’s plan for generic drug draws lawsuit from Abbott (GenericsWeb)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: